Address
Email address
Phone number
https://nanordica.comNanordica Medical OÜ | first-in-class wound care productNanordica Medical‘s first-in-class wound care products are designed to prevent infection and promote wound closure simultaneously.
Name
Nanordica Medical OÜ
Registry code
14710113
VAT number
EE102160673
Type
OÜ - Limited Liability Company
Status
Registered
Foundation date
23.04.2019 (5)
Financial year
01.01-31.12
Capital
16 662.52 €
Activity
72111 - Research and experimental development on biotechnology
2 880 €
113 042 €
3925%
5 390 €
(estimate is approximate)
185 020 €
6
Submitted
No tax arrears
61%
11%
| Owner | Representative | Beneficial owner | Roles | |
|---|---|---|---|---|
| OÜ Tikrikast 14476887 | 1% - 99.35 EUR | - | - | |
| Tatjana Bondarenko 28.06.1958 (66) | 0% - 71.51 EUR | - | - | |
| AS AMALFI 10411419 | 3% - 503.15 EUR | - | - | |
| HF Ventures I OÜ 16061050 | 3% - 434.00 EUR | - | - | |
| Olesja Bondarenko 28.08.1984 (40) | 19% - 3 093.89 EUR | Board member | Member of a higher management body, i.e. board member or supervisory board member | Founder |
| Sentosa Capital OÜ 10687713 | 2% - 298.06 EUR | - | - | |
| Anna-Liisa Kubo 13.08.1984 (40) | 17% - 2 892.63 EUR | Board member | Member of a higher management body, i.e. board member or supervisory board member | Founder |
| Meelis Kadaja 20.01.1979 (45) | 17% - 2 892.62 EUR | Board member | Member of a higher management body, i.e. board member or supervisory board member | |
| Grigory Vasiliev 22.12.1987 (36) | 16% - 2 691.37 EUR | Board member | Member of a higher management body, i.e. board member or supervisory board member | Founder |
| OÜ ANEMOS 11053577 | 1% - 238.45 EUR | - | - | |
| Tehnopol Ventures OÜ 16135392 | 1% - 229.89 EUR | - | - | |
| Usaldusfond Specialist VC Primary and Secondary Fund II 16392077 | 12% - 2 012.60 EUR | - | - | |
| Usaldusfond Superangel Two 16519922 | 6% - 1 006.30 EUR | - | - |
| 2019 19.05.2020 | 2020 30.03.2021 | 2021 08.03.2022 | 2022 18.04.2023 | 2023 31.05.2024 | |
|---|---|---|---|---|---|
| Total Revenue | - | 0 € | 0 € | 0 € | 2 880 € |
| Net profit (loss) for the period | -1 389 € | -117 € | -1 534 € | 39 379 € | 113 042 € |
| Profit Margin | - | - | - | - | 3925% |
| Current Assets | 2 336 € | 4 506 € | 340 € | 18 424 € | 753 771 € |
| Fixed Assets | - | 2 910 € | 5 600 € | 68 998 € | 250 892 € |
| Total Assets | 2 336 € | 7 416 € | 5 940 € | 87 422 € | 1 004 663 € |
| Current Liabilities | 725 € | 12 € | 10 € | 16 444 € | 819 643 € |
| Non Current Liabilities | - | 3 000 € | 3 000 € | 0 € | 0 € |
| Total Liabilities | - | 3 012 € | 3 010 € | - | - |
| Share Capital | - | - | - | - | - |
| Equity | 1 611 € | 4 404 € | 2 930 € | 70 978 € | 185 020 € |
| Employees | 0 | 0 | 0 | 1 | 6 |
| Turnover | State taxes | Labor taxes and payments | Employees | |
|---|---|---|---|---|
| 2024 Q1 | 15 470.6 € | 57 186.29 € | 61 993.2 € | 10 |
| 2023 Q4 | 28 440.72 € | 57 095.18 € | 61 899.98 € | 9 |
| 2023 Q3 | 18 480.27 € | 52 001.76 € | 56 378.84 € | 10 |
| 2023 Q2 | 14 845.13 € | 42 535.89 € | 46 112.68 € | 7 |
| 2023 Q1 | - | 29 409.92 € | 31 255.87 € | 6 |
| 2022 Q4 | 5 065 € | 6 349.09 € | 6 648.07 € | 1 |
| 2022 Q3 | 22 600 € | 4 585.2 € | 4 971.11 € | 1 |
| 2022 Q2 | 400 € | - | - | 1 |
| 2022 Q1 | - | - | - | - |
| 2021 Q4 | - | - | - | - |
| 2021 Q3 | - | - | - | - |
| 2021 Q2 | - | - | - | - |
| 2021 Q1 | 2 690 € | - | - | - |
| 2020 Q4 | - | - | - | - |
| 2020 Q3 | - | - | - | - |
| 2020 Q2 | - | - | - | - |
| 2020 Q1 | - | - | - | - |
